AI assistant
MANNKIND CORP — Director's Dealing 2021
May 20, 2021
31835_dirs_2021-05-20_a41614e8-36b9-4e09-8814-0549dfe456eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MANNKIND CORP (MNKD)
CIK: 0000899460
Period of Report: 2021-05-18
Reporting Person: Castagna Michael (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-18 | Restricted Stock Unit | A | 190092 | $0.00 | Acquired | 1307652 | Direct |
| 2021-05-18 | Restricted Stock Unit | A | 226000 | $0.00 | Acquired | 1533652 | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date.
F3: The restricted stock unit will vest on May 17, 2024 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 17, 2021. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 18, 2021 until May 17, 2024 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.